Mod GRF 1-29 & GHRP-2 Blend (10mg)

Description

Modified GRF 1-29 & GHRP-2 Peptide Blend

Overview

The Modified GRF 1-29 & GHRP-2 Peptide Blend is a synergistic combination of two synthetic peptides developed for the study of growth hormone (GH) synthesis, secretion, and regulation. Each compound targets distinct pathways in the growth hormone axis, and together, they demonstrate enhanced activity through dual receptor activation — Mod GRF 1-29 acting on GHRH receptors, and GHRP-2 acting on ghrelin (GHS-R1a) receptors.

Both peptides are being explored for their potential applications in metabolic research, including studies of cellular growth, tissue regeneration, appetite regulation, and endocrine signaling.

---

Chemical Composition

Form: Lyophilized powder
Purity: >99% (HPLC verified)
Storage: -20°C in a dry, dark environment
Intended Use: For laboratory research only. Not for human consumption.

---

Mechanism of Action

GHRP-2 (Growth Hormone Releasing Peptide-2)

GHRP-2 is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) that binds to ghrelin receptors (GHS-R1a) in the pituitary gland and hypothalamus. Activation of these receptors appears to stimulate both endogenous GH secretion and appetite-regulating pathways.

Mechanistically, GHRP-2:

• Activates ghrelin-mediated GHS-R1a receptors, promoting calcium ion influx and GH vesicle release.

• May influence arcuate nucleus neurons, enhancing growth hormone-releasing hormone (GHRH) secretion while suppressing somatostatin.

• Appears to increase IGF-1 synthesis through GH upregulation.

• Demonstrates orexigenic activity, leading to increased appetite and caloric intake in controlled studies.

---

Modified GRF 1-29 (CJC-1295 without DAC)

Modified GRF 1-29 is a synthetic analog of GHRH (Growth Hormone-Releasing Hormone) comprising the first 29 amino acids of native GHRH — the minimal sequence required to activate GHRH receptors on somatotroph cells of the anterior pituitary.

It includes four amino acid substitutions to enhance stability and half-life, providing a more sustained GH response compared to the native peptide.

Upon binding to GHRH receptors, Mod GRF 1-29:

• Activates the adenylyl cyclase → cAMP → PKA pathway, leading to calcium ion influx.

• Stimulates GH vesicle fusion and secretion into the bloodstream.

• Promotes cyclic pulsatile GH release, mimicking physiological secretion patterns.

---

Synergistic Mechanism

When used together, GHRP-2 and Mod GRF 1-29 exhibit synergistic effects by activating complementary GH release pathways:

• Mod GRF 1-29 triggers GH secretion via GHRH receptor stimulation, while

• GHRP-2 simultaneously stimulates ghrelin receptors (GHS-R1a), amplifying the amplitude and duration of GH release.

Experimental data suggest that combined administration may lead to a 54-fold increase in pulsatile GH secretion, compared to baseline levels observed with either peptide alone. (11)

---

Research Findings

1. Pharmacological Tolerability

Studies on animal models (guinea pigs and rabbits) have demonstrated that GHRP-2 has no significant toxicological or systemic side effects at GH-stimulating doses. Observed effects were limited to mild increases in intestinal motility, with no impact on cardiovascular, renal, or respiratory systems. (5)

---

2. Appetite and Metabolism

In controlled human studies, GHRP-2 increased food intake by approximately 35% compared to placebo groups, correlating with measurable elevations in circulating GH levels. These findings support the hypothesis that ghrelin receptor activation by GHRP-2 may induce hunger signaling and energy homeostasis regulation. (6)

---

3. Endocrine and Hormonal Effects

Clinical data suggest that GHRP-2 and Mod GRF 1-29 both stimulate GH, cortisol, ACTH, and prolactin release in male test subjects. The GH response was notably stronger in younger individuals, while older participants still demonstrated measurable hormonal increases. (10)

---

4. GH Deficiency Research

Animal and clinical models of growth hormone deficiency (GHD) have shown that these peptides may stimulate GH release via dual hypothalamic and pituitary mechanisms, potentially influencing sleep cycles, appetite regulation, and anabolic activity. (8)(9)

---

5. IGF-1 Stimulation

Combined administration of GHRP-2 and Mod GRF 1-29 has been associated with a 65% increase in circulating IGF-1 levels in controlled test settings. This suggests a downstream anabolic effect linked to GH activation. (11)

---

Summary of Research Applications

• Growth hormone axis regulation

• GH deficiency modeling

• Appetite and metabolism studies

• Muscle regeneration and recovery models

• Endocrine pathway mapping

• Synergistic receptor pharmacology

---

References

1. Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. Endotext. MDText.com, 2019. NCBI Bookshelf

2. Phung LT et al. Effects of GHRP-2 administration on GH release in swine. Domest Anim Endocrinol. 2001;20(1):9–19. PMID: 11164330

3. PubChem Compound Summary for CID 91976842, CJC-1295 Without DAC. PubChem

4. Roh SG et al. Mechanisms of action of GHRP-2 in bovine pituitary cells. J Anim Sci. 1997;75(10):2744–2748. PMID: 9331879

5. Furuta S et al. General pharmacology of KP-102 (GHRP-2). Arzneimittelforschung. 2004;54(12):868–880. PMID: 15646371

6. Laferrère B et al. GHRP-2, like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611–614. PMC2824650

7. Garcia JM, Merriam GR, et al. Growth Hormone Secretagogues in Endocrine Research. Endotext. 2019.

8. V Mericq et al. Effects of GHRP-2 in GH-deficient test subjects. Clin Endocrinol. (2000).

9. Mohtashami Z et al. GHS research in pediatric GH deficiency. J Endocrinol Metab Res. 2002.

10. Veldhuis JD et al. Impact of GHRP-2 on GH, ACTH, cortisol, and prolactin in adults. Endocrinology. (1998).

11. Lengyel G, et al. Growth Hormone Secretagogues and IGF-1 modulation: A comprehensive review. Peptides. (2012).

---